Johnson & Johnson (NYSE:JNJ) Stock Price Expected to Rise, Morgan Stanley Analyst Says

Johnson & Johnson (NYSE:JNJ) had its price objective hoisted by stock analysts at Morgan Stanley from $262.00 to $267.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Morgan Stanley’s target price indicates a potential upside of 11.39% from the company’s previous close.

Other equities research analysts have also recently issued research reports about the stock. BMO Capital Markets reaffirmed an “outperform” rating on shares of Johnson & Johnson in a research report on Thursday, December 11th. Daiwa Securities Group upped their price target on shares of Johnson & Johnson from $203.00 to $237.00 and gave the stock an “outperform” rating in a research report on Thursday, January 29th. Wall Street Zen cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Sanford C. Bernstein upped their price target on shares of Johnson & Johnson from $208.00 to $225.00 and gave the stock a “market perform” rating in a research report on Friday, January 23rd. Finally, HSBC upped their price target on shares of Johnson & Johnson from $265.00 to $280.00 and gave the stock a “buy” rating in a research report on Tuesday, March 17th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $238.17.

Johnson & Johnson Stock Down 0.7%

Shares of JNJ traded down $1.62 during mid-day trading on Friday, hitting $239.69. The company’s stock had a trading volume of 1,829,017 shares, compared to its average volume of 8,581,457. The company’s 50-day moving average is $241.07 and its 200-day moving average is $214.54. Johnson & Johnson has a 52-week low of $146.12 and a 52-week high of $251.71. The firm has a market capitalization of $577.33 billion, a price-to-earnings ratio of 21.69, a PEG ratio of 2.39 and a beta of 0.34. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.48.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. The firm had revenue of $24.28 billion during the quarter. On average, equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Insider Activity at Johnson & Johnson

In related news, EVP Timothy Schmid sold 22,623 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the completion of the transaction, the executive vice president owned 26,769 shares in the company, valued at $6,540,469.77. The trade was a 45.80% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Vanessa Broadhurst sold 6,197 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the transaction, the executive vice president owned 23,003 shares of the company’s stock, valued at approximately $5,598,700.17. This trade represents a 21.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 30,142 shares of company stock valued at $7,360,528. 0.16% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of JNJ. Blueline Advisors LLC acquired a new position in Johnson & Johnson during the 4th quarter valued at approximately $25,000. Abich Financial Wealth Management LLC acquired a new position in Johnson & Johnson during the 3rd quarter valued at approximately $26,000. Cresta Advisors Ltd. acquired a new position in Johnson & Johnson during the 4th quarter valued at approximately $26,000. Evolution Wealth Management Inc. acquired a new position in Johnson & Johnson during the 2nd quarter valued at approximately $27,000. Finally, Clayton Financial Group LLC acquired a new position in Johnson & Johnson during the 3rd quarter valued at approximately $28,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Multiple analyst upgrades and bullish notes have supported upside expectations for JNJ, with recent coverage lifting targets and signaling confidence in the company’s recovery and pipeline execution. Johnson & Johnson (NYSE:JNJ) Shares Up 1.1% on Analyst Upgrade
• Positive Sentiment: MedTech catalyst: J&J launched its VARIPULSE Pro pulsed field ablation system in Europe (CE Mark), adding a device growth opportunity and upcoming real‑world evidence that could support MedTech revenue momentum. Johnson & Johnson PFA Launch Puts VARIPULSE Pro And Valuation In Focus
• Positive Sentiment: Dividend profile remains a steady long‑term positive for income investors — J&J’s >60‑year streak of dividend increases keeps it on buy-and-hold lists despite near‑term noise. Could Buying This Dividend Pharma Stock Today Set You Up for Life?
• Neutral Sentiment: Fair value shift is marginal — one note nudged its fair value estimate from $241.08 to $241.71, indicating analysts see only modest upside from current levels; investors are parsing whether upgraded targets reflect durable change or near‑term optimism. How The Narrative On Johnson & Johnson (JNJ) Is Shifting With New Targets And Litigation Risks
• Neutral Sentiment: Analysts and consensus estimates are front‑and‑center ahead of Q1; Wall Street projections show drug growth and MedTech momentum but also flag headwinds — these previews set the stage for a reaction to actual Q1 results. Should You Buy, Sell or Hold JNJ Stock Ahead of Q1 Earnings?
• Negative Sentiment: Profit‑taking / valuation concern: a Seeking Alpha preview argues the recent rally may be overbought and suggests selling into strength, which can pressure the stock amid mixed signals. Johnson and Johnson Q1 Earnings Preview: Time To Sell The Rally?
• Negative Sentiment: Execution and litigation risks remain material — coverage highlights ongoing legal exposure and rising biosimilar/pricing pressure on key drugs, factors that could dent near‑term results and margins. How The Narrative On Johnson & Johnson (JNJ) Is Shifting With New Targets And Litigation Risks

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.